Alnylam Payables Turnover vs Capex To Revenue Analysis
ALNY Stock | USD 149.40 1.82 1.20% |
Alnylam Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alnylam Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alnylam Pharmaceuticals is a good investment. Please check the relationship between Alnylam Pharmaceuticals Payables Turnover and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
Payables Turnover vs Capex To Revenue
Payables Turnover vs Capex To Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alnylam Pharmaceuticals Payables Turnover account and Capex To Revenue. At this time, the significance of the direction appears to have very week relationship.
The correlation between Alnylam Pharmaceuticals' Payables Turnover and Capex To Revenue is 0.2. Overlapping area represents the amount of variation of Payables Turnover that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Alnylam Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Alnylam Pharmaceuticals' Payables Turnover and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Payables Turnover of Alnylam Pharmaceuticals are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Payables Turnover i.e., Alnylam Pharmaceuticals' Payables Turnover and Capex To Revenue go up and down completely randomly.
Correlation Coefficient | 0.2 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most indicators from Alnylam Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 7.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.41 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 704.1M | 868.6M | 1.5B | 1.6B | Total Revenue | 844.3M | 1.0B | 1.8B | 1.9B |
Alnylam Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Alnylam Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alnylam Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.4B | 3.4B | 3.6B | 3.5B | 3.8B | 4.0B | |
Other Current Liab | 206.5M | 393.8M | 494.1M | 585.7M | 713.0M | 748.7M | |
Total Current Liabilities | 956.4M | 1.1B | 1.2B | 767.9M | 967.8M | 1.0B | |
Total Stockholder Equity | 1.4B | 1.0B | 588.2M | (158.2M) | (220.6M) | (209.6M) | |
Property Plant And Equipment Net | 646.4M | 706.5M | 733.6M | 738.6M | 725.8M | 762.1M | |
Net Debt | (243.4M) | 24.6M | 177.6M | 453.9M | 1.9B | 2.0B | |
Retained Earnings | (3.7B) | (4.6B) | (5.4B) | (6.6B) | (7.0B) | (6.7B) | |
Accounts Payable | 49.9M | 52.0M | 73.4M | 98.1M | 55.5M | 28.9M | |
Cash | 547.2M | 496.6M | 820.0M | 866.4M | 812.7M | 853.3M | |
Non Current Assets Total | 661.2M | 1.2B | 774.5M | 854.1M | 847.2M | 889.5M | |
Non Currrent Assets Other | 18.1M | 500M | 40.9M | 115.5M | (3.5B) | (3.4B) | |
Other Assets | 32.9M | 40.7M | 101.1M | 115.5M | 132.8M | 139.4M | |
Cash And Short Term Investments | 1.5B | 1.9B | 2.4B | 2.2B | 2.4B | 2.6B | |
Common Stock Shares Outstanding | 109.3M | 115.0M | 118.5M | 121.7M | 124.9M | 70.4M | |
Short Term Investments | 989.0M | 1.4B | 1.6B | 1.3B | 1.6B | 1.7B | |
Liabilities And Stockholders Equity | 2.4B | 3.4B | 3.6B | 3.5B | 3.8B | 4.0B | |
Non Current Liabilities Total | 603.8M | 1.3B | 1.9B | 2.9B | 3.1B | 3.2B | |
Other Current Assets | 98.4M | 90.7M | 111.9M | 132.9M | 126.4M | 68.9M | |
Total Liab | 956.4M | 2.4B | 3.1B | 3.7B | 4.1B | 4.3B | |
Property Plant And Equipment Gross | 425.2M | 706.5M | 733.6M | 738.6M | 948.9M | 996.3M | |
Total Current Assets | 1.7B | 2.2B | 2.9B | 2.7B | 3.0B | 3.1B | |
Accumulated Other Comprehensive Income | (36.5M) | (43.6M) | (33.3M) | (44.7M) | (23.4M) | (22.2M) | |
Property Plant Equipment | 425.2M | 465.0M | 502.0M | 523.5M | 602.0M | 632.1M | |
Short Long Term Debt Total | 303.8M | 521.2M | 997.6M | 1.3B | 2.7B | 2.8B | |
Other Liab | 327.7M | 352.3M | 1.4B | 406.4M | 467.3M | 490.7M | |
Current Deferred Revenue | 396.2M | 352.3M | 301.8M | 42.1M | 102.8M | 119.3M | |
Other Stockholder Equity | 5.2B | 5.6B | 6.1B | 6.5B | 6.8B | 7.2B | |
Short Term Debt | 303.8M | 329.9M | 321.9M | 42.0M | 96.5M | 67.7M | |
Net Receivables | 43.0M | 102.4M | 198.6M | 238.0M | 327.8M | 344.2M | |
Common Stock Total Equity | 1.1M | 1.2M | 1.2M | 1.2M | 1.4M | 770.9K | |
Common Stock | 1.1M | 1.2M | 1.2M | 1.2M | 1.3M | 801.6K | |
Net Tangible Assets | 1.4B | 1.0B | 588.2M | (158.2M) | (182.0M) | (172.9M) | |
Retained Earnings Total Equity | (3.7B) | (4.6B) | (5.4B) | (6.6B) | (5.9B) | (5.6B) | |
Capital Surpluse | 5.2B | 5.6B | 6.1B | 6.5B | 7.4B | 7.8B | |
Inventory | 56.3M | 92.3M | 122.7M | 129.0M | 89.1M | 93.6M | |
Non Current Liabilities Other | 603.8M | 1.6B | 1.7B | 1.5B | 1.6B | 1.7B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
CEOs Directory Screen CEOs from public companies around the world | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 15.974 | Quarterly Revenue Growth 0.548 | Return On Assets (0.03) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.